Den Europæiske Union - dansk - EMA (European Medicines Agency)

ucb pharma sa - lacosamid - epilepsi - antiepileptika, - vimpat er indiceret som monoterapi og supplerende terapi til behandling af partielle anfald med eller uden sekundær generalisering hos voksne, unge og børn fra 4 år med epilepsi.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ucb pharma ltd - natriumoxybat - cataplexy; narcolepsy - andre narkotika stoffer - behandling af narkolepsi med katapleksi hos voksne patienter.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamid - epilepsier, delvis - antiepileptika, - lacosamide ucb er angivet som monoterapi og tillægsbehandling terapi i behandlingen af delvis-anfald med eller uden sekundær generalisering hos voksne, unge og børn fra 4 år med epilepsi.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ucb pharma s.a. - romosozumab - osteoporose - narkotika til behandling af knoglesygdomme - evenity er indiceret til behandling af svær osteoporose hos postmenopausale kvinder med høj risiko for knoglebrud.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptika, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

chemvet pharma aps - budesonid - kapsler med modificeret udløsning, hårde - 3 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

viatris aps - lactulose - oral opløsning - 667 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

chemvet pharma aps - quetiapin fumarat - filmovertrukne tabletter - 100 mg